注射用胰激肽原酶联合芪明颗粒治疗早期糖尿病肾病的临床研究  

Clinical Study of Kallidinogenase Injection Combine With Qiming Particle in Treatment of Early Phase Diabetic Nephropathy

作　　者：凌宏威[1] 陈文君[1] 刘璇[1] 应长江[1] 李伟[1] 

机构地区：[1]江苏省徐州医学院附属医院,221002

出　　处：《中国继续医学教育》2015年第29期211-212,共2页China Continuing Medical Education

摘　　要：目的探讨注射用胰激肽原酶联合芪明颗粒在治疗早期糖尿病肾病中的效果。方法随机选取2013年1月-2014年4月我院收治的早期糖尿病肾病患者65例作为研究对象,随机分为怡开治疗组和联合治疗组。治疗14 d后,比较两组患者的临床治疗效果和治疗前后的变化,并进行分析。结果与怡开治疗组比较,联合治疗组在治疗后患者的尿微量白蛋白的变化更为明显。结论注射用胰激肽原酶联合芪明颗粒在治疗早期糖尿病肾病中,可以有效提高临床疗效。Objective To exploer the effect of kallidinogenase injection combine with qiming particle in treatment of early phase diabetic nephropathy.MethodsSelected 65 cases of early diabetic nephropathy patients from January 2013 to April 2014 in our hospital as the research object, were randomly divided into the diet therapy group and the combined treatment group. 14 days after treatment, compared two groups of patients with the clinical treatment effect and the change of the before and after treatment, and analyzed.Results Compared with grace open treatment group, combined treatment group after treatment in patients with the change of the urine trace albumin was more apparent.Conclusion Kallidinogenase injection combine with qiming particle in treatment of early phase diabetic nephropathy has certain clinical value, can effectively improve the patient＇s clinical curative effect.

关 键 词：注射用胰激肽原酶 芪明颗粒 糖尿病肾病 临床研究 

分 类 号：R587[医药卫生—内分泌]